Press Releases

February 11, 2021
– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU launch, with focus on market access – – Expansion opportunity beyond PFIC and beyond odevixibat – – Commercial management to host conference call and webcast today
January 22, 2021
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases BOSTON , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid
January 14, 2021
BOSTON , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.
January 7, 2021
BOSTON , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST .